Skip to content
Menu
Home
About
ABOUT FIREBRICK
HISTORY
OUR VALUES
OUR TEAM
News
Investors
Contact
News
31 Oct 2024
Launch of Nasodine promotion to HCPs in Singapore
Read More
9 Sep 2024
Firebrick Consultant to drive Pharmacy Distribution in Singapore
Read More
9 Sep 2024
Nasodine European Marketing Application filed and passed validation
Read More
15 Aug 2024
New agreement allows Nasodine launch in Philippines
Read More
13 Jun 2024
Firebrick Launches Nasodine in Singapore via Nasodine-sg.com
Read More
17 May 2024
Firebrick Raises $800,000 via Placement
Read More
17 Apr 2024
Firebrick Pharma launches Nasodine in the US via Nasodine.com
Read More
29 Nov 2023
Nasodine COVID-19 patent granted
Read More
16 Nov 2023
Nasal disinfection as a front-line defence in future pandemics
Read More
15 Nov 2023
Firebrick Investor Update
Read More
3 Oct 2023
Update on Nasodine Trial and Forward Plans
Read More
9 Aug 2023
Firebrick Phase 3 Trial fully recruited with 500 subjects
Read More
7 Aug 2023
Nasodine COVID-19 Trial Achieves Primary Endpoint
Read More
20 Jun 2023
Investor Update on Key Projects
Read More
31 May 2023
Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
Read More
9 May 2023
Nasodine Patent Allowed in Canada
Read More
1 May 2023
Firebrick Raises $1 million via Placement
Read More
3 Apr 2023
Nasodine COVID-19 Trial Concludes Recruitment – Results in June 2023
Read More
21 Mar 2023
Firebrick Pharma’s Phase 3 Trial of Nasodine Resumes
Read More
22 Feb 2023
Firebrick pursues development of Nasodine for use in children
Read More
18 Jan 2023
Nasodine research points to potential role in CRS
Read More
30 Nov 2022
Firebrick’s international trial gets radio spotlight
Read More
14 Nov 2022
Nasodine composition patent accepted in Australia
Read More
2 Nov 2022
Update on Nasodine Phase 3 trial
Read More
25 Oct 2022
Nasodine patent granted in Singapore
Read More
14 Sep 2022
Firebrick announces formation of Scientific Advisory Board
Read More
25 May 2022
Nasodine now patented in 26 countries
Read More
25 May 2022
Firebrick appoints Dr Richard Treagus as director
Read More
17 May 2022
Channel 7 shines a spotlight on Firebrick’s Phase 3 common cold trial for Nasodine
Read More
4 May 2022
Peter Molloy discusses the common cold trial on global finance platform Grafa
Read More
3 May 2022
Nasodine Phase 3 common cold trial underway
Read More
26 Apr 2022
Nasodine trial in COVID-19 started
Read More
1 Mar 2022
Firebrick to file appeal seeking immediate approval of Nasodine
Read More
17 Feb 2022
US Patent Granted for Nasodine in COVID-19
Read More
10 Feb 2022
Peter Molloy on the Nasodine SARS-CoV-2 data and the Firebrick vision
Read More
10 Feb 2022
Nasodine in vitro and pilot human COVID-19 studies published
Read More
3 Feb 2022
Peter Molloy on Firebrick’s successful ASX debut and plans for Nasodine
Read More
1 Feb 2022
South African trial of Nasodine in COVID-19 receives local approval to proceed
Read More
28 Jan 2022
Firebrick launch on ASX receives national media attention
Read More
27 Jan 2022
Firebrick Pharma to debut on the ASX
Read More
MENU
Home
About
ABOUT FIREBRICK
HISTORY
OUR VALUES
OUR TEAM
News
Investors
Contact
